-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] In recent years, benefiting from the resonance of favorable policies, talents, capital and other factors, the innovation and transformation of the domestic pharmaceutical industry has accelerated, and the number of innovative drugs has shown a blowout growth
.
With continuous R&D investment, many local pharmaceutical companies have significantly accelerated their innovation, and their innovation achievements have also yielded fruitful results
.
For example, the 2021 financial report shows that Simcere Pharma China has launched 5 innovative drugs with differentiated value, and the sales revenue of innovative drugs in 2021 will account for 62.
4% of the total revenue of the whole group
.
In terms of R&D investment, it will reach 1.
417 billion yuan in 2021, accounting for 28.
3% of the total revenue, and create nearly 60 innovative R&D pipelines
.
Hengrui Medicine's R&D investment in the first three quarters of 2021 has exceeded 4 billion yuan.
The company's continuous high R&D investment has brought benefits to the company.
In addition to the 10 innovative drugs that have been listed, Hengrui has more than 50 innovative drugs under clinical development.
, more than 240 clinical trials have been carried out at home and abroad
.
According to the annual report of Fosun Pharma, the total R&D investment in 2021 is 4.
975 billion yuan, a year-on-year increase of 24.
28%.
Build and form technology platforms such as small molecule innovative drugs, antibody drugs, and cell therapy, and actively explore cutting-edge technology fields such as RNA, oncolytic viruses, gene therapy, and targeted protein degradation
.
During the reporting period, a number of new products of the company continued to increase in volume rapidly, including a number of innovative products such as Yikaida (Aquilence Injection) and Slulimumab Injection, which were successively approved or entered the key clinical/approval stage; New products such as Bitai (mRNA new crown vaccine), tumor drugs Hanlikang, Hanquyou, and chronic liver disease drug Su Kexin have been approved for marketing, effectively hedging the pressure of price reductions on stock varieties from centralized drug procurement
.
Innovation and R&D are also the engines and core competitiveness of BeiGene's long-term development.
The company is transforming from a Biotech (biotechnology) to a global Biopharma (biopharmaceutical) enterprise.
In 2021, its R&D expenses will be 9.
282 billion yuan, a slight increase from 2020.
4%
.
At present, BeiGene's commercial product portfolio has reached more than 16 models, of which the self-developed BTK inhibitor zanubrutinib has become the first domestic innovative anti-tumor drug successfully launched overseas.
It has been approved in many countries and regions, and the company has also established in-depth business cooperation with multinational giants such as Novartis, Celgene, and Amgen
.
It is reported that at the 2022 American Association for Cancer Research (AACR) annual meeting held in April this year, more than 40 domestic innovative pharmaceutical companies announced more than 150 preclinical/clinical research results, many of which were BeiGene (Tislelizumab) Anti-), Hengrui Medicine (adbelimumab), Junshi Bio (toripalimab), Corning Jereh (KN026+KN046), Betta Pharmaceuticals (icotinib), Haihe Pharmaceuticals (Gumetinib) and other positive clinical data, further demonstrating the domestic innovation and strength
.
In terms of the number of publications, Qilu Pharma has published 11 research results, followed by JiCui Yaokang, which has published 10 mouse models, and BeiGene has published 9 results.
In addition, there are Betta Pharmaceuticals, Antengene Pharmaceuticals , Primis Bio, Simcere, Ascentage, etc.
have disclosed a number of achievements
.
From the perspective of clinical progress, AACR focused projects mainly focus on preclinical research, but there are also many major clinical stage trial results announced
.
In addition, from the perspective of project types, domestic innovative pharmaceutical companies are mainly deployed in small molecules, monoclonal antibodies, double antibodies, ADCs and other fields
.
Among them, Jicui Yaokang and Biositu focus on a number of cutting-edge mouse model research, Gracell’s CD19/CD7 dual-targeted CAR-T therapy, and Qihan Bio’s iPSC-CAR-NK therapy are the representatives of domestic cell therapy
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
With continuous R&D investment, many local pharmaceutical companies have significantly accelerated their innovation, and their innovation achievements have also yielded fruitful results
.
For example, the 2021 financial report shows that Simcere Pharma China has launched 5 innovative drugs with differentiated value, and the sales revenue of innovative drugs in 2021 will account for 62.
4% of the total revenue of the whole group
.
In terms of R&D investment, it will reach 1.
417 billion yuan in 2021, accounting for 28.
3% of the total revenue, and create nearly 60 innovative R&D pipelines
.
Hengrui Medicine's R&D investment in the first three quarters of 2021 has exceeded 4 billion yuan.
The company's continuous high R&D investment has brought benefits to the company.
In addition to the 10 innovative drugs that have been listed, Hengrui has more than 50 innovative drugs under clinical development.
, more than 240 clinical trials have been carried out at home and abroad
.
According to the annual report of Fosun Pharma, the total R&D investment in 2021 is 4.
975 billion yuan, a year-on-year increase of 24.
28%.
Build and form technology platforms such as small molecule innovative drugs, antibody drugs, and cell therapy, and actively explore cutting-edge technology fields such as RNA, oncolytic viruses, gene therapy, and targeted protein degradation
.
During the reporting period, a number of new products of the company continued to increase in volume rapidly, including a number of innovative products such as Yikaida (Aquilence Injection) and Slulimumab Injection, which were successively approved or entered the key clinical/approval stage; New products such as Bitai (mRNA new crown vaccine), tumor drugs Hanlikang, Hanquyou, and chronic liver disease drug Su Kexin have been approved for marketing, effectively hedging the pressure of price reductions on stock varieties from centralized drug procurement
.
Innovation and R&D are also the engines and core competitiveness of BeiGene's long-term development.
The company is transforming from a Biotech (biotechnology) to a global Biopharma (biopharmaceutical) enterprise.
In 2021, its R&D expenses will be 9.
282 billion yuan, a slight increase from 2020.
4%
.
At present, BeiGene's commercial product portfolio has reached more than 16 models, of which the self-developed BTK inhibitor zanubrutinib has become the first domestic innovative anti-tumor drug successfully launched overseas.
It has been approved in many countries and regions, and the company has also established in-depth business cooperation with multinational giants such as Novartis, Celgene, and Amgen
.
It is reported that at the 2022 American Association for Cancer Research (AACR) annual meeting held in April this year, more than 40 domestic innovative pharmaceutical companies announced more than 150 preclinical/clinical research results, many of which were BeiGene (Tislelizumab) Anti-), Hengrui Medicine (adbelimumab), Junshi Bio (toripalimab), Corning Jereh (KN026+KN046), Betta Pharmaceuticals (icotinib), Haihe Pharmaceuticals (Gumetinib) and other positive clinical data, further demonstrating the domestic innovation and strength
.
In terms of the number of publications, Qilu Pharma has published 11 research results, followed by JiCui Yaokang, which has published 10 mouse models, and BeiGene has published 9 results.
In addition, there are Betta Pharmaceuticals, Antengene Pharmaceuticals , Primis Bio, Simcere, Ascentage, etc.
have disclosed a number of achievements
.
From the perspective of clinical progress, AACR focused projects mainly focus on preclinical research, but there are also many major clinical stage trial results announced
.
In addition, from the perspective of project types, domestic innovative pharmaceutical companies are mainly deployed in small molecules, monoclonal antibodies, double antibodies, ADCs and other fields
.
Among them, Jicui Yaokang and Biositu focus on a number of cutting-edge mouse model research, Gracell’s CD19/CD7 dual-targeted CAR-T therapy, and Qihan Bio’s iPSC-CAR-NK therapy are the representatives of domestic cell therapy
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
